Non-Alzheimer degenerative dementias

Current Opinion in Neurology

Volumn 11, Issue 5, 1998, Pages 417-427

  Pasquier, Florence ^a   Delacourte, André ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BIOCHEMISTRY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE CLASSIFICATION; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; LEWY BODY; MOLECULAR GENETICS; PRIMARY PROGRESSIVE APHASIA; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

DEMENTIA; FRONTAL LOBE; HUMANS; LEWY BODIES; TAU PROTEINS; TEMPORAL LOBE;

EID: 0031784830     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199810000-00002     Document Type: Review

References (129)

1. Dalla Barba G, Boller F. Non-Alzheimer degenerative dementias. Curr Opin Neurol 1994; 7:305-309.
2. Brun A, Englund E, Gustafson L, Passant U, Mann DMA, Neary D, Snowden JS. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57:416-418.
3. Gregory CA, Hodges JR. Frontotemporal dementia: use of consensus criteria and prevalence of psychiatric features. Neuropsychiatr Neuropsychol Behav Neurol 1996; 9:145-153.
4. Miller BL, Ikonte C, Ponton M, Levy M, Boone K, Darby A, et al. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. Neurology 1997; 48:937-942. A study of the sensitivity and specificity of the Lund-Manchester items in separating FTD from Alzheimer's disease. Autopsy confirming FTD was performed in nine out of 30 FTD patients
5. Pasquier F, Petit H. Frontotemporal dementia: its rediscovery. Eur Neurol 1997; 38:1-6. An historical and practical overview of FTD is presented.
6. Litvan I, Agid Y, Sastrj N, Jankovic J, Wenning GK, Goetz CG, et al. What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathological study. Neurology 1997; 49:62-69. When clinicians suspect Pick's disease, their diagnosis is almost always correct.
7. Pasquier F, Lebert F, Lavenu I, Petit H. Clinical diagnosis of frontotemporal dementia [in French]. Rev Neurol (Paris) 1998; 154:217-223. A description is presented of the misdiagnosis and clinical features in a cohort of 74 FTD patients followed up in a memory clinic.
8. Traykov L, Boller F. Frontal lobes pathology and dementia. An appraisal of the contribution of Leonardo Bianchi. Int J Neurol Sci 1997; 18:129-134. This study leads to tricky neuropsychological questions on the real functions of frontal lobes, when older literature is referred to.
9. Neary D, Kertesz A, Hachinski V. Frontotemporal degeneration, Pick's disease, and corticobasal degeneration. One entity or 3? Arch Neurol 1997; 54:1425-1429. A summary of the debate is presented.
10. Snowden JS, Neary D, Mann DMA. Fronto-temporal lobar degeneration: Fronto-temporal dementia, progressive aphasia, semantic dementia. New York: Churchill Livingstone; 1996.
11. Pasquier F, Lebert F, Scheltens P. Frontotemporal dementia. Dordrecht, The Netherlands: ICG Publications; 1996.
12. Kertesz A, Munoz DG. Pick's disease and Pick complex. New York: Wiley-Liss; 1998. This book presents the clinical concepts related to Pick's disease as well as biological, genetic, neuropathological issues. Topical questions are raised.
13. Amouyel Ph, Richard F. Epidemiology of frontotemporal dementia. In: Frontotemporal dementia. Pasquier F, Lebert F, Scheltens Ph (editors). Dordrecht, The Netherlands: ICG Publications; 1996. pp. 11-17.
14. Stevens M, van Duijn CM, Kamphorst W, de Knijff P, Heutink P, van Gool WA, et al. Familial aggregation in frontotemporal dementia. Neurology 1998; 50:1541-1545. This is the first large population-based epidemiological study of FTD.
15. Stevens M, van Duijn CM, de Knijff P, van Broeckhoven C, Heutink P, Oostra BA, et al. Apolipoprotein E gene and sporadic frontal lobe dementia. Neurology 1997; 48:1526-1529.
16. Gustafson L, Abrahamson M, Grubb A, Nilsson K, Fex G. Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord 1997; 8:240-243.
17. Geschwind D, Karrim J, Nelson SF, Miller B. The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementa. Ann Neurol 1998; 44:134-138.
18. Minthon L, Hesse C, Sjögren M, Englund E, Gustafson L, Blennow K. The apolipoprotein E ∈4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Neurosci Lett 1997; 226:65-67. This is a small study, but it has a high rate of histological confirmation.
19. Barber R, Snowden JS, Craufurd D. Frontotemporal dementia and Alzheimer's disease: retrospective differentiation using information from informants. J Neurol Neurosurg Psychiatry 1995; 59:61-70.
20. Hooten WM, Lyketsos CG. Differentiating Alzheimer's disease and frontotemporal dementia: receiver operator characteristic curve analysis of four rating scales. Dement Geriatr Cogn Disord 1998; 9:164-174 This is an original way of assessing the diagnostic value of much used bedside tests.
21. Levy ML, Miller BL, Cummings JL, Fairbanks LA, Craig A. Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch Neurol 1996; 53:687-690.
22. Rozzini L, Lussignoli G, Padovani A, Bianchetti A, Trabucchi M. Alzheimer disease and frontotemporal dementia [letter]. Arch Neurol 1997; 54:350.
23. Kertesz A, Davidson W, Fox H. Frontal Behavioral Inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 1997; 24:29-36. An operational scale with a cutoff and a high discriminating value is presented.
24. Mendez MF, Perryman KM, Miller BL, Cummings JL. Behavioral differences between frontotemporal dementia and Alzheimer's disease: a comparison on the BEHAVE-AD rating scale. Int Psychogeriatr 1998; 10:155-162.
25. Lebert F, Pasquier F, Souliez L, Petit H. Frontotemporal behavioral scale. Alzheimer Dis Assoc Disord (in press). This is an operational and discriminant scale for early dementia, grouping the affective and behavioural items under four dimensional headings.
26. Miller BL, Darby A, Benson DF, Cummings JL, Miller MH. Aggressive, socially disruptive and antisocial bejaviour associated with frontotemporal dementia. Br J Psychiatry 1997; 170:150-155. This study highlights the serious social consequence of FTD, with legal implications, and the relationship between frontotemporal dysfunction and certain types of antisocial activities. It is supported by eight autopsy confirmations of FTD.
27. Swartz JR, Miller BL, Lesser IM, Booth R, Darby A, Wohl M, Benson F. Behavioral phenomenology in Alzheimer's disease, frontotemporal dementia, and late-life depression: a retrospective analysis. J Geriatr Psychiatry Neurol 1997; 10:67-74. This is a retrospective study on noncognitive behavioural symptoms that isolated a subset of symptoms accurately classifying FTD, Alzheimer's disease and late-life depression.
28. Mendez MF, Perryman KM, Miller BL, Swartz JR, Cummings JL. Compulsive behaviors as presenting symptoms of frontotemporal dementia. J Geriatr Psychiatry Neurol 1997; 10:154-157.
29. Edwards-Lee T, Miller BL, Benson F, Cummings JL, Russell GL, Boone K, Mena I. The temporal variant of frontotemporal dementia. Brain 1997; 120:1027-1040. A careful case study is presented that indicates the heterogenity of FTD (with a high proportion of individuals with Pick's disease).
30. Lebert F, Pasquier F, Petit H. Personality traits and frontal lobe dementia. Int J Geriatr Psychiatry 1995; 20:1047-1049.
31. Miller BL, Ponton M, Benson DF. Enhanced artistic creativity with temporal lobe degeneration. Lancet 1996; 348:1744-1745. This paper shows that some skills are preserved, and even improved, in the course of DFT as will as in Alzheimer's disease.
32. Pasquier F, Hamon M, Lebert F, Jacob B, Pruvo J-P, Petit H. Medial temporal lobe atrophy in memory disorders. J Neurol 1997; 244:175-181.
33. Kitagaki H, Mori E, Hirono N, Ikejiri Y, Ishii K, Imamura T, et al. Alteration of white matter MR signal intensity in frontotemporal dementia. AJNR Am J Neuroradiol 1997; 18:367-378. A promising study is presented.
34. Kaufer DI, Miller BL, Itti L, Fairbanks LA, Li J, Fishman J, et al. Midline cerebral morphometry distinguishes frontotemporal dementia and Alzheimer's disease. Neurology 1997; 48:978-985. This result requires confirmation in a larger group of patients.
35. Pasquier F, Lavenu I, Lebert F, Jacob B, Steinling M, Petit H. The use of SPECT in a multidisciplinary memory clinic. Dement Geriatr Cogn Disord 1997; 8:85-91. The limits of SPECT for diagnostic purposes are outlined.
36. Warkentin S, Passant U. Functional imaging of the frontal lobes in organic dementia. Dement Geritr Cogn Disord 1997; 8:105-109.
37. Didic M, Giusiano B, de Laforte C, Ceccaldi M, Poncet M. Identification of clinical subtypes of frontotemporal dementia and cerebral blood flow on SPECT: preliminary results. Alzheimer's Rep 1998; 1:179-185.
38. Grossman M, Payer F, Onishi K, D'Esposito M, Morrison D, Sadek A, Alavi A. Language comprehension and regional cerebral defects in frontotemporal degeneration and Alzheimer's disease. Neurology 1998; 50:157-163.
39. Pasquier F, Lebert F, Grymonprez L, Petit H. Verbal fluency in dementia of frontal lobe type and in dementia of Alzheimer type. J Neurol Neurosurg Psychiatry 1995; 58:81-84.
40. Gregory CA, Orrell M, Sahakian B, Hodges JR. Can frontotemporal dementia and Alzheimer's disease be differentiated using a brief battery of tests? Int J Geriatr Psychiatry 1997; 12:375-383.
41. Pasquier F. Neuropsychological features and cognitive assessement in frontotemporal dementia. In: Frontotemporal dementia. Pasquier F, Lebert F, Scheltens Ph (editors). Dordrecht, The Netherlands: ICG Publications; 1996. pp. 49-69.
42. Lindau M, Almkvist O, Johansson S-E, Wahlund L-O. Cognitive and behavioral differentiation of frontal lobe degeneration of the non-Alzheimer type and Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9:205-213.
43. Souliez L, Pasquier F, Lebert F, Leconte P, Petit H. Generation effect in short term verbal and visuospatial memory: comparisons between dementia of Alzheimer type and dementia of frontal lobe type. Cortex 1996; 32:347-356.
44. Grossman M, D'Esposito M, Hughes E, Onishi K, Biassou N, White-Devine T, Robinson KM. Language comprehension progiles in Alzheimer's disease, multi-infarct dementia, and frontotemporal degeneration. Neurology 1996; 47:183-189.
45. Cappa SF, Binetti G, Pezzini A, Padovani A, Rozzini L, Trabucchi M. Object and action naming in Alzheimer's disease and frontotemporal dementia. Neurology 1998; 50:351-355. A nice neuropsychological study is presented.
46. Mendez MF, Cherrier M, Perryman KM, Pachana N, Miller BL, Cummings JL. Frontotemporal dementia versus Alzheimer's disease: differential cognitive features. Neurology 1996; 47:1189-1194.
47. Pachana NA, Boone KB, Miller BL, Cummings JL, Berman N. Comparison of neuropsychological functioning in Alzheimer's disease and frontotemporal dementia. J Int Neuropsychol Soc 1996; 2:505-510.
48. Sjögren M, Wallin A, Edman A. Symptomatological characteristics distinguish between frontotemporal dementia and vascular dementia with a dominant frontal lobe syndrome. Int J Geriat Psychiatry 1997; 12:656-661.
49. Cherrier MM, Mendez MF, Perryman KM, Pachana NA, Miller BL, Cummings JL. Frontotemporal dementia versus vascular dementia: differential feature on mental status examination. J Am Geriatr Soc 1997; 45:579-583.
50. Lavenu I, Pasquier F, Lebert F, Pruvo JP, Petit H. Explicit memory in frontotemporal dementia: the role of medial temporal atrophy. Dement Geriatr Cogn Disord 1998; 9:99-102. These results require confirmation by neuropathological studies.
51. Minthon L, Edvinsson L, Gustafson L. Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. Dement Geritr Cogn Disord 1997; 8:232-239.
52. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58:212-216. This well documented open study should stimulate pharmaceutical clinical research.
53. Hollister RD, Xia M, McNamara MJ, Hyman BT. Neuronal expression of class II major histocompatibility complex (HLA-DR) in 2 cases of Pick disease. Arch Neurol 1997; 54:243-248.
54. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, et al. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 1994; 44:1878-1884
55. Wijker M, Wszolek ZK, Wolters ECH, Rooimans MA, Pals G, Pfeiffer RF, et al. Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-pono-nigral degeneration to chromosome 17q21. Hum Mol Genet 1996; 5:151-154.
56. Dark F. A family with atuosomal dominant, non-Alzheimer's presenile dementia. Aust NZ J Psychiatry 1997; 31:139-144.
57. Baker M, Kwok BJ, Kucera S, Crook R, Farrer M, Houlden H, et al. Localization of frontotemporal dementia with parkinsonism in an Australian kindred to chromosome 17q21-22. Ann Neurol 1997; 42:794-798.
58. Petersen RB, Tabaton M, Chen SG, Monari L, Richardson SL, Lynches T, et al. Familial progressive subcortical gliosis: presence of prions and linkage to chromosome 17. Neurology 1995; 45:1062-1067.
59. Heutink P, Stevens M, Rizzu P, Bakker E, Kros JM, Tibben A, et al. Hereditary frontotemporal dementia is linked to chromosome 17q21-22: a genetic and clinico-pathological study of three Dutch families. Ann Neurol 1996; 41:150-159.
60. Basun H, Almkvist O, Axelman K, Brun A, Campbell TA, Collinge J, et al. Clinical characteristics of a chromosome 17-linked rapidly progressive familial frontotemporal dementia. Arch Neurol 1997; 54:539-544.
61. Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, Ghetti B. Familial multiple system tauopathy with presenile dementia; a disease with abundant neuronal and glial Tau filaments. Proc Natl Acad Sci U S A 1997; 94:4113-4118.
62. Murrel JR, Koller D, Foroud T, Goedert M, Spillantini MG, Edenberg HJ, et al. Familial multiple system tauopathy with presenile dementia is localized to chromosome 17. Am J Hum Genet 1997; 61:1131-1138.
63. Yamaoka LH, Welsh-Bohmer KA, Hulette CM, Gaskell PC Jr, Murray M, Rimmler JL, et al. Linkage of frontotemporal dementia to chromosome 17: clinical and neuropathological characterization of phenotype. Am J Hum Genet 1996; 59:1306-1312.
64. Bird TD, Wijsman EM, Nochlin D, Leehey M, Sumi SM, Payami H, et al. Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. Neurology 1997; 48:949-954.
65. Bird TD. Genotypes, phenotypes, and frontotemporal dementia. Take your pick. Neurology 1998; 50:1526-1527. This clear editorial summarizes the recent advances on chromosome-17 families.
66. Foster NL, Wilhelmsen K, Sima AAF, Jones MZ, D'Amato CJ, Gilman S, and conference participants. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997; 41:706-715. This represents an important step in the understanding of FTD.
67. Lendon CL, Lynch T, Norton J, McKeel DW, Busfield F, Craddock N, et al. Hereditary dysphasic disinhibition dementia: a frontotemporal dementia linked to 17q21-22. Neurology 1998; 50:1546-1555. This very important and comprehensive paper describes various phenotypes of FTD-17.
68. Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 1998; 8:387-402.
69. Wilhemsen KC. Frontetemporal dementia is on the MAPtau. Ann Neurol 1997; 41:139-140.
70. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998; 43:815-825.
71. Hutton M, Lendon CL, Rizzu P, Baker M, Froedlich S, Houlden H, et al. Association of missense and 5-splice site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393:702-705. This is a big step forward in the understanding of degenerative diseases.
72. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998; 95:7737-7741. This work has major implications for FTD, as well as for Alzheimer's disease and other tauopathies.
73. Brown J, Ashworth A, Gydesen S, Sorensen A, Rossor M, Hardy J, Collinge J. Familial non-specific dementia maps to chromosome 3. Hum Mol Genet 1995; 4:1625-1628.
74. Kertesz A, Munoz D. Pick's disease, frontotemporal dementia, and Pick complex. Emerging concepts. Arch Neurol 1998; 55:302-304. An interesting review is presented.
75. Abe K, Ukita H, Yanagihara T. Imaging in primary progressive aphasia. Neuroradiology 1997; 39:556-559.
76. Otsuki M, Soma Y, Sato M, Homma A, Tsuji S. Slowly progressive pure word deafness. Eur Neurol 1998; 39:135-140.
77. Tyler LK, Moss HE, Patterson K, Hodges J. The gradual deterioration of syntax and semantics in a patient with progressive aphasia. Brain Lang 1997; 56:426-476.
78. Croot K, Patterson K. Single word production in non fluent progressive aphasia. Brain Lang 1998; 61:226-273.
79. Broussole E, Bakchine S, Tommasi M, Laurent B, Bazin B, Cinotti L, et al. Slowly progressive anarthria with late anterior opercular syndrome: a variant form of frontal cortical atrophy syndromes. J Neurol Sci 1996; 144:44-58.
80. de Koning I, van Doom AP, van Dongen HR. Slowly progreszsive isolated dysarthria: longitudinal course, speech features, and neuropsychological deficits. J Neurol 1997; 244:664-667.
81. Chapman SB, Rosenberg RN, Weiner MF, Shobe A. Autosomal dominant progressive syndrome of motor-speech loss without dementia. Neurology 1997; 49:1298-1306.
82. Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS. Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 1997; 48:959-969. This anatomopathological study of 11 patients with corticobasal degeneration shows the overlap with other neurodegenerative diseases.
83. Bergeron C, Pollanen MS, Weyner L, Lang AE. Cortical degeneration in progressive supranuclear palsy. A comparison with cortico-basal ganglionic degeneration. J Neuropathol Exp Neurol 1997; 56:726-734.
84. Otsuki M, Soma Y, Yoshimura N, Tsuji S. Slowly progressive limb-kinetic apraxia. Eur Neurol 1997; 37:100-103.
85. Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortico-basal ganglionic degeneration: differentiation from Alzheimer's disease. Neurology 1996; 46:720-726.
86. Moreau O, Naegele B, Pellat J. The nature of apraxia in corticobasal degeneration. A case of melokinetic apraxia. Neuropsychiatry Neuropsychol Behav Neurol 1996; 9:288-292.
87. Mimura M, White RF, Albert ML. Corticobasal degeneration: neuro-psychological correlates. J Neuropsychiatr Clin Neurosci 1997; 9:94-98.
88. Case Report of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-1997. A 64-year-old man with progressive dementia, seizures, and unstable gait. N Engl J Med 1997; 337:549-556.
89. Litvan I. The clinical and pathologic hallmarks of progressive supranuclear palsy. Curr Opin Neurol 1997; 10:346-350. An expert review is presented.
90. Kosaka K, Iseki E. Dementia with Lewy bodies. Curr Opin Neurol 1996; 9:271-275.
91. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113-1124.
92. Perry R, McKeith I, Perry E. Dementia with Lewy bodies. Clinical, pathological, and treatment issues. Cambridge: Cambridge University Press; 1996.
93. McKeith IG. Dementia with Lewy bodies: clinical and pathological diagnosis. Alzheimer's Rep 1998; 1:83-87. A clear review is presented.
94. Drach LM, Steinmetz HE, Wach S, Bohl J. High proportion of dementia with Lewy bodies in the postmortems of a mental hospital in Germany. Int J Geriatr Psychiatry 1997; 12:301-306. In 103 consecutive postmortems, DLB (associated with Alzheimer's disease pathology) was the third case of dementia, after Alzheimer's disease and Alzheimer's disease associated with vascular pathology.
95. Hansen LA, Samuel W. Criteria for Alzheimer's disease and the nosology of dementia with lewy bodies. Neurology 1997; 48:126-132. This paper represents a step in the classification of DLB.
96. Revesz T, McLaughlin JL, Rossor MN, Lantos PL. Pathology of familial Alzheimer's disease with Lewy bodies. J Neural Transm Suppl 1997; 51:121-135.
97. Samuel W, Alford M, Hofstetter CR, Hansen L. Dementia with Lewy bodies versus pure Alzheimer disease: difference in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997; 56:499-508. This is a convincing study.
98. Walker Z, Allen RL, Shergill S, Katona CL. Neuropsychological performance in Lewy body dementia and Alzheimer's disease. Br J Psychiatry 1997; 170:156-158.
99. Graham C, Ballard C, Saad K. Variables which distinguish patients fulfilling clinical criteria for dementia with Lewy bodies from those with Alzheimer's disease. Int J Geriatr Psychiatr 1997; 12:314-318.
100. Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P. Motor and cognitive functionin Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1997; 62:243-252. This is a careful and comprehensive clinical study, by experienced authors, but it lacks neuropathological confirmation.
101. Mouly C, Grymonprez L, Pasquier F, Lebert F, Lavenu I, Jacob B, Petit H. Implicit and explicit visual memory in Alzheimer disease, frontotemporal dementia and dementia with Lewy body. Alzheimer's Rep 1998; 1:61-64
102. Connor DJ, Salmon DP, Sandy TJ, Galasko D, Hansen LA, Thal LJ. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol 1998; 55:994-1000. A standardized neuropsychological comparison between matched groups of confirmed Alzheimer's disease and DLB patients is presented.
103. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathological study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology 1996; 47:1148-1149.
104. Ballard C, McKeith I. Psychiatric features in diffuse Lewy body disease [letter]. Neurology 1998; 50:573.
105. Ballard C, McKeith I, Harrison R, O'Brien J, Thompson P, Lowery K, et al. A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy Bodies and Alzheimer's disease. Int Psychogeriatr 1997; 9:381-388. This type of detailed clinical description is very useful to clinical practice.
106. Ala TA, Yang KH, Sung JH, Frey WH. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1997; 62:16-21. This is a useful although retrospective study. Patients with microscopical or gross brain infarcts, which are confounding conditions, were excluded.
107. Ballard C, McKeith I, Burn D, Harrison R, O'Brien J, Lowery K, et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997; 96:366-371.
108. Louis ED, Klatka LA, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997; 48:376-380.
109. Lippa CF, Johnson R, Smith TW. The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease. Ann Neurol 1998; 43:102-106. This important neuropatholological finding will be useful to clinicians.
110. Imamura T, Ishii K, Sasaki M, Kitagaki H, Yamaji S, Hirono N, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett 1997; 235:49-52. A consistant study with neuropathological data is presented.
111. Varma AR, Talbot PR, Snowden JS, Lloyd JJ, Testa HJ, Neary D. A 99mTc-HMPAO single-photon emission computed tomography study of Lewy body disease. J Neurol 1997; 244:349-359.
112. Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998; 51:125-130.
113. Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998; 10:227-229. Very useful to know.
114. Geroldi C, Frisoni GB, Bianchetti A, Trabucchi M. Drug treatment in Lewy body dementia. Dement Geriatr Cogn Disord 1997; 8:188-197.
115. Dickson DW. Neurodegenerative diseases with cytoskeletal pathology: a biochemical classification. Ann Neurol 1997; 42:541-544. This paper presents an interesting classification that is updated here because important biochemical data have been obtained in the past year (the different sets of Tau isoforms in Pick's disease and CBD, Tau mutations in FTDP-17, synuclein in neuronal inclusion of multisystem atrophy, etc.).
116. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, et al. Huntington-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997; 90:549-558. This important paper shows how the genetic defect in Huntington's chorea could inhibit the function of a protein, leading to neurodegeneration.
117. Delacourte A, Buee L. Normal and pathological Tau proteins as factors for microtubule assembly. Int Rev Cytol 1997; 171:167-224. A review on Tau pathologies is presented.
118. Buee-Scherrer V, Buee L, Leveugle B, Pert DP, Vermersch P, Hof PR, Delacourte A. Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer's disease and other neurodegenerative disorders. Ann Neurol 1997; 42:356-359.
119. Auer IA, Schmidt ML, Lee VMY, Curry B, Suzuki K, Shin RW, et al. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol 1995; 90:547-551.
120. Buée-Scherrer V, Buée L, Hof PR, Leveugle B, Gilles C, Loerzel AJ, et al. Neurofibrillary degeneration in amyotrophic lateral sclerosisi parkinsonism-dementia complex of Guam - immunochemical characterization of tau proteins. Am J Pathol 1995; 146:924-932.
121. •].
122. •] explain the relationship between lesions and cognitive impairment: the most important variables are not the lesions, but their location and number in the different brain areas.
123. Buée-Scherrer V, Hof PR, Buée L, Leveugle B, Vermersch P, Perl DP, et al. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. Acta Neuropathol 1996; 91:351-359.
124. •].
125. •] emphasize the role of Tau isoforms with exon 10 in PSP, CBD and FTDP-17.
126. Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 1998; 43:193-204.
127. Strong C, Anderton BH, Perry RH, Perry EK, Ince PG, Lovestone S. Abnormally phosphorylated tau protein in senile dementia of Lewy body type and Alzheimer disease: evidence that the disorders are distinct. Alzheimer Dis Assoc 1995; 9:218-222.
128. Vaughan JR, Farrer MJ, Wszolek ZK, Gasser T, Durr A, Agid Y, et al. Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). Hum Mol Genet 1998; 7:751-753.
129. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839-840. This is an important discovery for all diseases involving Lewy bodies.